Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 6 : Hundreds of safety violations in Wake Schools uncovered in WRAL investigation raise questions of student safety.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
28.00
+0.08 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
November 04, 2022
Gainers
Via
Benzinga
Why Are Apellis Pharmaceuticals Shares Falling Today?
November 04, 2022
Via
Benzinga
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
November 04, 2022
Apellis long said it wouldn't wait for 24-month data for its eye drug. Apellis was wrong.
Via
Investor's Business Daily
Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket
November 04, 2022
Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday.
Via
Benzinga
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
November 03, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Apellis Pharmaceuticals Stands With Analysts
September 08, 2022
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Via
Benzinga
Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years
August 24, 2022
Via
Benzinga
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
November 03, 2022
Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH)
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
October 31, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Apellis Pharmaceuticals Stands With Analysts
August 09, 2022
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Via
Benzinga
7 Analysts Have This to Say About Apellis Pharmaceuticals
October 18, 2022
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
October 04, 2022
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
October 03, 2022
Both companies presented data at the American Academy of Ophthalmology meeting.
Via
Investor's Business Daily
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
October 04, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...
Via
Benzinga
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
October 03, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Via
Benzinga
Investigator Says Apellis' Lead Product Shows 'First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth'
October 03, 2022
Via
Benzinga
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
September 30, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
September 30, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
September 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
September 08, 2022
Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the...
Via
Benzinga
Moderna To $165? Plus This Analyst Cuts PT On FedEx
September 08, 2022
Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to...
Via
Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
August 25, 2022
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Via
Benzinga
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
August 25, 2022
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
August 24, 2022
Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in...
Via
Benzinga
7 Cheap Biotech Stocks to Buy Now
August 03, 2022
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.
Via
InvestorPlace
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 27, 2022
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.